Open-label safety assessment of bilastine in elderly patients with allergic rhinoconjunctivitis and/or urticaria

Sologuren, Ander; Viñas, R; Cordón, Esther; Riesgo, Susana E; Forés, María Del Mar; Senán, María Rosa; Fernández, Sonia Mateos; Labeaga, Luis; Ruiz-Miján, Manuel

doi:10.2500/aap.2018.39.4136

Cited by 14 publications

(12 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overall, this study showed that bilastine 20 mg once daily had a favourable safety profile, with a low incidence of TEAEs, in elderly patients with allergic rhinoconjunctivitis and/or urticaria. Moreover, the safety profile in elderly patients was not different from that in placebocontrolled clinical trials in which adverse event rates reported for bilastine were similar to those for placebo 75 .…”

Section: Elderly Patientsmentioning

confidence: 69%

“…In clinical trials performed as part of the European development programme for bilastine, only 69 patients were aged 65 years, of whom 34 received bilastine 75 . Consequently, a prospective observational study in a real-world practice setting was undertaken to evaluate the safety profile in 146 patients aged 65 years with allergic rhinoconjunctivitis and/or urticaria who were prescribed bilastine 20 mg once daily and followed up for 3 months 75 . The mean ± SD age of participants was 74.8 ± 6.6 years; 74% had allergic rhinoconjunctivitis, 19% had urticaria and 7% had both disorders.…”

Section: Elderly Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Bilastine: a lifetime companion for the treatment of allergies

Church

Tiongco-Recto

Ridolo

et al. 2019

Current Medical Research and Opinion

View full text Add to dashboard Cite

Objective: Bilastine is a potent and highly selective H 1 -antihistamine approved for the treatment of allergic rhinoconjunctivitis and urticaria. This article summarizes available data on the use of bilastine in the treatment of allergic disorders in different age groups, including younger and older adults, and school-age children and adolescents. Methods: A PubMed literature search ("bilastine") was conducted on 25 February 2019. Additional literature known to the authors and identified from the reference lists of cited publications was included. Results: Bilastine is administered orally at a dose of 20 mg once daily in adults and adolescents aged 12 years and 10 mg once daily in children aged 6 to <12 years. Clinical trials have demonstrated its efficacy at improving nasal and ocular symptoms in patients with allergic rhinitis, and wheals and itching in patients with urticaria. It has a rapid onset of action and long duration of action. Bilastine does not undergo significant metabolism and does not interact with the CYP450 system, which limits its potential for drug-drug interactions. No dosage adjustments are required in patients with renal or hepatic impairment, or in the elderly. Bilastine is generally well tolerated, even when administered at above-standard doses. It does not exhibit anticholinergic effects or cardiotoxic effects, shows no central nervous system penetration and has minimal sedative properties. It has been shown to improve health-related quality of life. Conclusions: Bilastine is a suitable option for the treatment of patients with allergic rhinoconjunctivitis or urticaria across age groups from school-age children to elderly patients.

show abstract

Section: Elderly Patientsmentioning

confidence: 69%

Section: Elderly Patientsmentioning

confidence: 99%

Bilastine: a lifetime companion for the treatment of allergies

Church

Tiongco-Recto

Ridolo

et al. 2019

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

“…18,26,48 In a prospective study, bilastine 20 mg was well tolerated by patients with 65 years or more age. 49 No environmental concerns exist from bilastine use in patients with urticaria. 19…”

Section: Tolerability and Adverse Events With Bilastinementioning

confidence: 99%

Bilastine for the treatment of chronic spontaneous urticaria: Consensus statement for Indian patients

Godse¹,

De²,

Zawar³

et al. 2021

IJCED

View full text Add to dashboard Cite

Urticaria or hives is a common skin condition that affects population with a lifetime prevalence of up to 22% and point prevalence of 1%. Antihistamines play a very important role in the treatment of chronic urticaria. International guidelines recommend second-generation, non-sedating H1-antihistamines as the first line therapy for management of chronic urticaria. Uncontrolled symptoms in many patients demand a new antihistamine which offers significant efficacy without or with minimal adverse events especially sedation. Bilastine, a second generation H1-antihistamine, offers significant benefits over most antihistamines including once daily dosage, significant efficacy in relieving symptom, minimal risk of drug to drug interactions and adverse events. This consensus statement is prepared to discuss the role of bilastine in the management of chronic urticaria among Indian patients. Comprehensive review of published literature was done to prepare a draft of consensus statement. The draft was circulated to the experts for their review and comments. Final document was prepared with incorporation of their comments.

show abstract

“…In the wheal and flare test on healthy volunteers, bilastine onset of action occurred within 1 h and reduction of itching sensation was better than that of desloratadine (p < 0.05) and for rupatadine (p < 0.01) [16 ]. No dosage adjustments are needed in patients with mild, moderate, or severe renal impairment, with hepatic impairment, and in elderly subjects, overall endorsing a good tolerability profile [17, 18 ]. Bilastine has a high affinity for the P‐gP efflux pump, and this effect restricts transit across the blood–brain barrier and limits the potential for sedation [14, 15 ].…”

Section: Main Textmentioning

confidence: 99%

The safety and tolerability profile of bilastine for chronic urticaria in children

Papadopoulos

Zuberbier

2019

Clin Transl Allergy

View full text Add to dashboard Cite

BackgroundUrticaria is a condition defined by the development of wheals, angioedema or both. It is classified based on its duration as acute (≤ 6 weeks) or chronic (> 6 weeks). Chronic urticaria is less frequent than acute one in children, but it represents a debilitating condition, always needing treatment. Symptoms affect child’s daily activities and disturb sleeping patterns, causing emotional distress and negatively influencing learning and cognition. Therefore, the management of chronic urticaria must point to a complete control of symptoms, taking into account tolerability and the patient quality of life.Review of literatureThe recently revised version of EAACI/GA2LEN/EDF/WAO guideline on the management of urticaria, in addition to recommending the use of second-generation H1 antihistamines as the treatment of choice, gives particular attention to their use in the paediatric population. Bilastine has been studied in children; at the dose of 10 mg/once daily, it is licenced for the symptomatic relief of urticaria in children ≥ 6 to 11 years, in the European Union, in appropriate formulation, as oral solution or orodispersible tablet.ConclusionsIn line with the recent guideline recommendation for the use of second generation H1 antihistamines in children we have reviewed the safety and tolerability profile of bilastine in children with chronic urticaria.

show abstract

Open-label safety assessment of bilastine in elderly patients with allergic rhinoconjunctivitis and/or urticaria

Cited by 14 publications

References 0 publications

Bilastine: a lifetime companion for the treatment of allergies

Bilastine: a lifetime companion for the treatment of allergies

Bilastine for the treatment of chronic spontaneous urticaria: Consensus statement for Indian patients

The safety and tolerability profile of bilastine for chronic urticaria in children

Contact Info

Product

Resources

About